[Original Article]

Effects of Y-27632, a ROCK inhibitor on Human Corneal Endothelial Cells Cultured by Isolating Human Corneal Endothelial Progenitor cells

Haeeun Shin, MD¹, Joon Ki Min, MD¹, Na Rae Kim, MD, PhD¹, Kyoung Yul Seo, MD, PhD², Hee Seung Chin, MD, PhD¹, Soyoung Lee³, Ji Won Jung MD, PhD¹

¹Department of Ophthalmology and Inha Vision Science Laboratory, Inha University School of Medicine, Incheon, South Korea
²Department of Ophthalmology, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea
³Translational Research Center, Inha University School of Medicine, Incheon, South Korea

Corresponding Author: Ji Won Jung, MD, PhD
Department of Ophthalmology, Inha University Hospital, 27, Inhang-Ro, Jung-gu, Incheon 22332, South Korea
Tel.: 82-32-890-2400
Fax: 82-32-890-2403
E-mail: panch325@gmail.com
ABSTRACT

Purpose: Human corneal endothelial progenitor cells (HCEPs), which have been selectively isolated and differentiated into human corneal endothelial cells (HCECs), are crucial for repairing corneal endothelial damage. In this study, we evaluated the roles of a ROCK inhibitor, Y-27632, on the isolation and expansion of HCEPs, and assessed the in vitro effects of different concentrations of Y-27632 on the differentiated HCEPs (HCECs).

Methods: HCEPs were isolated and expanded in a medium with and without 10 μM Y-27632, and then differentiated into HCECs in a medium with FBS. The characteristics of HCEP and differentiated HCEPs (HCECs) were confirmed by immunofluorescence staining. The proliferation, viability, morphology, and wound healing ability of HCECs were assessed in the presence of different concentrations of Y-27632.

Results: Y-27632 enabled the isolation and expansion of HCEPs from the corneal endothelium. The differentiated HCEPs (HCECs) showed an optimal increase in proliferation and survival in the presence of 10 μM Y-27632. As the concentration of Y-27632 increased, differentiated HCEPs (HCECs) became elongated, and actin filaments were redistributed to the periphery of cells. Y-27632 also caused a concentration-dependent enhancement in the wound healing ability of differentiated HCEPs (HCECs).

Conclusions: Y-27632 enabled the isolation and expansion of HCEPs. It also enhanced the proliferation, viability, and migration of differentiated HCEPs (HCECs).

Key Words: human corneal endothelial progenitor cells, differentiated human corneal endothelial progenitor cells, human corneal endothelial cells, ROCK inhibitor, corneal endothelial dysfunction
INTRODUCTION

Human corneal endothelial cells (HCECs) have limited proliferative potential in vivo,\(^1\)\(^2\) therefore, damage to corneal endothelial cells (CECs) leads to irreversible endothelial dysfunction and corneal edema. The conventional treatment of severe corneal endothelial dysfunction is corneal transplant, which consists of either the entire corneal layer or only the posterior lamellar corneal layer, derived from donated corneal tissue. To overcome the shortage of donor corneas, transplantation of cultivated HCECs has been suggested as an alternative treatment.\(^3\)-\(^9\) Many groups have successfully cultured and amplified HCECs in vitro, and treated animal models with corneal endothelial dysfunction.\(^10\),\(^11\) However, there are no defined protocols for the clinical application of cultured HCECs. In addition, current corneal endothelial engineering has restriction, such as limited proliferative ability, fibroblastic transformation, and cellular senescence.\(^12\)-\(^18\)

Several studies have reported the presence of human corneal endothelial progenitor cells (HCEPs).\(^19\)-\(^23\) Hara et al.\(^24\) had established a method for culturing HCEPs and differentiating them into HCECs. They had suggested that, unlike conventional HCEC culture, HCEPs could be selectively expanded with high proliferative potency and to generate transplantable CEC sheets.\(^24\) Using progenitor cells in this manner could help overcome the limitations of corneal endothelial engineering.

Recently, cultured CECs were injected into the anterior chamber of the eye along with an inhibitor of Rho associated coiled-coil forming protein kinase (ROCK).\(^18\) ROCK inhibition enhanced cell engraftment at the posterior corneal layer, enabling the cell-based treatment of corneal endothelial dysfunction.\(^18\),\(^25\) This was consistent with many reports that demonstrated that the inhibition of ROCK signaling decreased apoptosis and increased proliferation and cellular adhesion in the CECs cultured by various methods.\(^12\),\(^18\),\(^26\)

The aim of this study was to evaluate the role of the ROCK inhibitor, Y-27632, on the isolation and expansion of HCEPs, and to assess the in vitro effects of different concentrations of Y-27632 on the differentiated HCEPs (HCECs). The results of the study might contribute to cell injection treatments of differentiated HCEPs (HCECs), for corneal endothelial dysfunction.

MATERIALS AND METHODS

The study protocol was approved by the Inha University Hospital Institutional Review Board,
Incheon, South Korea (IRB no. 2016-05-018), and adhered to the guidelines of the Declaration of Helsinki. Written informed consent was obtained from the next of kin of all deceased donors. Ten human peripheral corneal tissues from 8 donors (mean donor age, 54.6 ± 19.4 years) were obtained by trephination with 7.0 mm trephines and stored in storage medium (OptiSol-GS, Bausch & Lomb, Rochester, NY, USA) at 4 °C.

Isolation and expansion of HCEPs

HCEPs were isolated and cultured as previously described by Hara et al.24 Briefly, Descemet's membranes with HCECs were stripped from the human corneas using sterile surgical forceps. The tissue was transferred to an enzyme cell detachment medium (Accutase; Life Technologies, Carlsbad, USA) at 37°C for 30 min, and centrifuged at 15,000 rpm for 5 min. The cells were seeded at a density of 100–300 cells per cm² onto culture plates coated with 20 μg/mL laminin-511 (BioLamina, Stockholm, Sweden).

The culture medium comprised Dulbecco’s modified Eagle’s medium/nutrient mixture F-12 (DMEM/F12), supplemented with 20% knockout serum replacement (KSR), 2mM L-glutamine, 1% non-essential amino acids, 100 μM 2-mercaptoethanol, 50U/mL penicillin G, and 50 μg/mL streptomycin (all from Life Technologies) along with 4 ng/mL basic fibroblast growth factor (bFGF) and 10μM Y-27632 (both from Wako Pure Chemical Industrials, Ltd, Osaka, Japan). Paired corneas from two donors were used to compare the expansion of HCEPs with and without 10μM Y-27632. HCEPs were cultured in a humidified atmosphere with 5% CO₂ at 37°C, and the culture medium was changed every 2–3 days. When the cells reached confluence, they were harvested with Accutase and passaged at ratios of 1:2 to 1:4.

Differentiation of HCEPs into differentiated HCEPs (HCECs)

HCEPs were differentiated into HCECs on culture plates coated with FNC coating mix (AthenaES, Baltimore, USA). The differentiation medium was composed of low-glucose DMEM with 10% fetal bovine serum (FBS), 50 U/mL penicillin G, and 50 μg/mL streptomycin (all from Life Technologies). The differentiated HCEPs (HCECs) were cultured in a humidified atmosphere with 5% CO₂ at 37°C. When the cells reached 70% confluency, they were harvested with 0.05% Trypsin-EDTA (Life Technologies) and passaged at a ratio of 1:4. The differentiated cells were viewed using optical microscope (Olympus CKX41; Olympus, Tokyo, Japan).
Immunofluorescence staining for characterizing of the HCEPs and the differentiated HCEPs (HCECs)

The HCEPs and differentiated HCEPs (HCECs) were cultured on 8 well culture slides (BD Biosciences, Oxford, UK) for immunofluorescence staining. They were fixed with 80% acetone at -20°C for 10 min, and nonspecific absorption was blocked with an antibody diluent solution (Life Technologies) at 37°C for 20 min. The cells were incubated overnight at 4°C with the primary antibodies against p75 neurotrophin receptor (p75NTR; 1:100, Merck Millipore, Darmstadt, Germany), SOX9 (1:100, Abcam, Cambridge, UK), ZO-1 (1:100, Life Technologies), and Na⁺/K⁺-ATPase (1:100, Merck Millipore) in an antibody diluent solution. They were washed three times in phosphate-buffer saline with 0.1% Tween 20 (PBS-T). The cells were then incubated for 2 h in a 1:200 dilution of rhodamine-labeled goat anti-mouse IgG and human serum absorbed fluorescein labeled goat anti-rabbit IgG (both from KPL, Gaithersburg, USA), and again washed three times in PBS-T in the dark. To stain the nuclei, the cells were stained with 4',6-diamidino-2-phenylindole, dihydrochloride (DAPI; Thermo, Rockford, USA) for 5 min. After mounting, the cells were observed using a fluorescence microscope (Olympus BX43; Olympus), and images were processed using the ISCapture Professional Imaging Software (Tucson, Fujian, China).

Protein expression analysis by western blot

RIPA Buffer (50mM Tris-HCl, 100mM NaCl, 5mM EDTA, 1% Sodium Deoxycholate, 4% Triton X-100, 0.4% SDS) containing a protease and phosphatase inhibitor mini tablets (Thermo scientific, Rockford, USA) was used for isolation of total cellular proteins. Western blotting was conducted using standard protocols. The 5% bovine serum albumin (BSA, Amresco, USA) in Tris (hydroxymethyl) aminomethane-buffered saline (pH 7.4) with 0.01% Tween 20 (TBS-T) was used for blocking the nonspecific binding for 1 h. Primary antibodies were ZO-1/TJP1 antibody (Thermo Fisher Scientific, Rockford, USA, 1:200 dilution), Na⁺/K⁺-ATPase antibody (Merck Millipore, Darmstadt, Germany, 1:200 dilution). A horseradish peroxidase (HRP) conjugated secondary antibody with a ECL Prime Western Blotting Detection reagent (GE Healthcare, Illinois, USA) was used for detection of immunoreactive bands.

Ki67 immunofluorescence staining of differentiated HCEPs (HCECs)

The differentiated HCEPs (HCECs) were cultured on 8-well culture slides (BD Biosciences) with and without 10 μM Y-27632 for 24 h and fixed and incubated overnight at 4°C with purified mouse anti-
Ki67 antibodies (1:100, BD biosciences, Dickinson, USA). The cells were then incubated with goat anti-mouse secondary antibodies for 2 h as described in the previous section, and washed three times in PBS-T in the dark. The nuclei were stained with DAPI, and cells were visualized as previously described.

**Cell viability assay of differentiated HCEPs (HCECs) treated with Y-27632**

The differentiated HCEPs (HCECs) were plated at a density of 2,000 cells/well on 96-well plates in a medium containing 0, 5, 10, and 30 μM Y-27632 for 24 h. The number of viable differentiated HCEPs (HCECs) was determined using the cell counting kit-8 (CCK-8; Dojindo Molecular Technologies, Inc., Rockville, USA). Absorbance was measured at 450 nm to determine cell viability in each well using a Universal Microplate Reader ELx800G (BioTek Instruments, Inc, Winooski, USA).

**Morphological assessment of differentiated HCEPs (HCECs) treated with Y-27632**

The differentiated HCEPs (HCECs) were stained with immunofluorescent actin to evaluate their morphologic changes when treated with the different concentrations of Y-27632. The cells were cultured on 8-well culture slides with 0, 5, 10, and 30 μM Y-27632 for 24 h. The cells were fixed and incubated overnight at 4°C in 1:200 dilution Alexa Fluor 594-conjugated phalloidin (Life Technologies), and washed three times with PBS-T. After counterstaining with DAPI, the cells were visualized in a fluorescence microscope as described in previous sections.

**Wound healing assessment of differentiated HCEPs (HCECs) treated with Y-27632**

The differentiated HCEPs (HCECs) were cultured until confluence in 60-mm culture dishes and scraped with a 200-μL plastic pipette tip. The unattached cells were washed away in PBS before the remaining cells were incubated in media with 0, 5, 10, and 30 μM Y-27632. The extent of the wound was determined by estimating the area between cells at the two opposite edges of the defect. Images of migrating of cells were obtained using an optical microscope, and relative wound sizes were analyzed using the ImageJ software (National Institutes of Health, Bethesda, MD, USA) after 0, 6, 24 and 48 h of incubation.

**Statistical analysis**

All the data are represented as mean ± standard deviation. Statistical significance was determined using Student’s t-test for single comparison and one-way ANOVA, followed by Tukey’s test for multiple comparisons. \( P < 0.05 \) was considered statistically significant.
RESULTS

ROCK inhibitor, Y-27632, enables HCEP isolation and expansion

A comparative study was performed on paired corneas from two donors (48 and 46 years old) to evaluate the role of Y-27632 in the isolation and expansion of HCEPs. When 10 μM Y-27632 was added, HCEPs from both donors were successfully isolated and expanded on a laminin-511-coated dish, while HCEPs were not observed in the absence of Y-27632, even after 30 days of culture (Fig 1). The cells had a bipolar, spindle-shaped morphology, and expressed the neural crest markers, p75NTR and SOX9, which are known markers of HCEPs.24 HCEPs from the corneas of eight donors were sub-cultured for several passages (mean numbers of passages, 4.8 ± 1.8) (Fig 2).

Differentiation of HCEPs into HCECs and characterization of differentiated HCEPs (HCECs)

We confirmed that HCEPs in low passages (below 3 passages) were differentiated into HCECs in the differentiation medium. The morphology of differentiated HCEPs (HCECs) changed from bipolar and spindle-shaped to confluent and hexagonal through the passages (mean numbers of passages, 7.8 ± 2.1) (Fig 3A). In addition, the differentiated HCEPs (HCECs) displayed characteristic expression of ZO-1 and Na⁺/K⁺-ATPase in the plasma membrane (Fig 3B) and this confirmed by western blotting (Fig 3C).

Effects of Y-27632 on the differentiated HCEPs (HCECs)

We used the differentiated HCEPs (HCECs) from passage 2~7, which confirmed the expression of ZO-1 and Na⁺/K⁺-ATPase.

1) Proliferation assessment of differentiated HCEPs (HCECs) treated with Y-27632

To determine the effects of Y-27632 on the proliferation of differentiated HCEPs (HCECs), we used Ki67 immunostaining as a reliable marker of cell proliferation. The differentiated HCEPs (HCECs) treated with 10 μM Y-27632 had significantly more Ki67 positive cells than the untreated control cells ($P = 0.028$) (Fig 4).

2) Cell viability assay of differentiated HCEPs (HCECs) treated with Y-27632

To determine the optimal concentration of Y-27632 required for obtaining viable differentiated HCEPs (HCECs), we performed a cell viability assay after 24 h exposure to different concentrations of Y-27632. The number of adherent and viable differentiated HCEPs (HCECs) increased as the Y-27632 concentration increased from 0 to 10 μM, then decreased at a 30 μM concentration ($P = 0.003$). At 10
μM, viability was significantly higher than that in the untreated control \( (P = 0.006, \text{Fig 5}) \).

3) Morphological assessment of differentiated HCEPs (HCECs) treated with Y-27632

The effect of Y-27632 on the morphology of differentiated HCEPs (HCECs) was examined by immunostaining with phalloidin, which is used to assess the distribution pattern of actin filaments. As the concentration of Y-27632 increased, the differentiated HCEPs (HCECs) lost their polygonal shape and became more elongated. The differentiated HCEPs (HCECs) remained polygonal at concentrations of Y-27632 below 10 μM. With 30 μM Y-27632, a large proportion of differentiated HCEPs (HCECs) showed the elongated morphology. The actin filaments were also altered, changing from a central radial distribution into a peripheral distribution along the plasma membrane (Fig 6).

4) Wound healing assessment of differentiated HCEPs (HCECs) treated with Y-27632

We observed a concentration-dependent enhancement in the wound healing ability of differentiated HCEPs (HCECs) treated with Y-27632. In response to the wound, differentiated HCEPs (HCECs) became elongated and fibroblast-like in appearance, and began to migrate from the scraping edge. At both 24 and 48 h, after treatment with 10 or 30 μM Y-27632, statistically significant increases in wound closure rate, were observed, compared to the untreated control (at 24 h, \( P = 0.005 \) and \( P < .001 \); at 48 h, \( P = 0.005 \) and \( P = 0.018 \)) (Fig 7).

DISCUSSION

Many studies have used various culture methods and supplements for transplanting cultured corneal endothelial cells, as an alternative treatment for corneal endothelial dysfunction.\(^3\)\(^-\)\(^{11}\) However, there are several limitations to this method, and no defined protocols have been established for clinical application. Many groups have tried to resolve the current limitations in conventional HCEC amplification,\(^10,11\) and the use of corneal endothelial progenitor cells has also been explored.\(^{24}\) HCEPs have been suggested to retain the proliferative capacity at the peripheral cornea.\(^{19-23,27}\)

In this study, we isolated and expanded HCEPs from peripheral corneas using KSR-based serum-free media supplemented with bFGF and laminin-511,\(^{24}\) which have been used to maintain undifferentiated cells, such as human embryonic stem cells and mesenchymal stem cells.\(^{24,28,29}\) Laminin-511 was considered important for isolating and expanding HCEPs, because the substrate has been used in the serum-free culture of human embryonic stem cells, and is present in the corneal
Descemet's membrane,\textsuperscript{24,30,31}

We cultured HCEPs using a protocol previously described by Hara et al.\textsuperscript{24} who had briefly treated the stripped Descemet's membranes with Y-27632 at the initial stage only, not throughout the culture period. Furthermore, they did not study the effects of Y-27632 on the culture method. In our study, we demonstrated that Y-27632 was necessary for the isolation and expansion of HCEPs. This finding was consistent with the results of many previous reports that demonstrated a significant increase in the adhesion of HCECs cultured with Y-27632.\textsuperscript{12,32} In one study, the addition of Y-27632 into a dual media culture system resulted in a 2-3 fold higher yield of CECs.\textsuperscript{33} ROCK signaling is known to be involved in cell adhesion, morphogenesis, migration, and cell cycle progression.\textsuperscript{34} A selective ROCK inhibitor, Y-27632, which is associated with increased adhesion and enhancement of actomyosin contractility, has been used for the \textit{in vitro} culture of CECs in corneal endothelial regenerative medicine for several years.\textsuperscript{12,32-34}

Our results showed that bipolar, spindle-shaped HCEPs expressed p75NTR and SOX9, which are markers of neural crest cells.\textsuperscript{35,36} Hara et al.\textsuperscript{24} had reported that HCEPs had partially retained the properties of the neural crest and periocular mesenchyme and showed high expression of p75NTR, SOX9, and FOXC2. Another study had reported that bovine corneal endothelial precursor cells, isolated with a sphere-forming assay, expressed the neural crest stem cell marker, nestin, and that these cells had the potential to differentiate into CECs.\textsuperscript{19,24} In our study, HCEPs also differentiated into hexagonal HCECs in a medium with FBS. Thus, cultivating HCECs from isolated HCEPs with high proliferative potency could be a novel source of cells for treating corneal endothelial dysfunction, as demonstrated in the results of our study, as well as those of previous reports.\textsuperscript{19,24}

In a recent study, cultivated CECs with Y-27632, were directly injected into the anterior chamber of the eye, and this turned out to be a significant success in corneal regenerative medicine.\textsuperscript{18} The ROCK inhibitor, Y-27632, increased the adhesion of injected cells onto the recipient cornea without any substrate, and thus helped in treating corneal endothelial dysfunction in animal models.\textsuperscript{12,18,34} Therefore, as a first step towards the use of HCECs cultivated by isolating HCEPs for cell injection treatments, we evaluated the \textit{in vitro} effects of Y-27632 on these HCECs, with the aim of determining the optimal concentration of Y-27632.

Consisting with previous findings,\textsuperscript{12,26,34,37,38} our results showed that ROCK inhibition with 10 \( \mu \text{M} \)
Y-27632 promoted the proliferation and survival of HCECs. ROCK inhibitors are thought to control the expression of cyclin D and p27 via PI 3-kinase signaling, thus promoting CEC proliferation. Previous studies have revealed the role of ROCK signaling in the regulation of pro- and anti-apoptotic, as well as cell survival signaling. However, to confirm whether Y-27632 treatment was sufficient to induce HCECs proliferation, further research is needed as the other studies demonstrated conflicting results.

In this study, Y-27632 caused a concentration-dependent change in HCEC morphology; as the cells became elongated, and actin filaments were redistributed to the periphery. Y-27632 also enhanced wound healing via cell migration and morphologic changes in HCECs, which was consistent with the results of previous studies. The cell migration involved membrane protrusion through cytoskeleton modification. Pipparelli et al. had revealed that the inhibition of ROCK signaling resulted in morphological changes in HCECs, characterized by loss of their polygonal shape and a remodeling of the cytoskeleton, as demonstrated by the redistribution of actin to the cell periphery. They proposed that the mechanism behind the enhanced wound healing effect of Y-27632 was associated with the regulation of the actin cytoskeleton.

Most studies have used a concentration around 10 to 30 μM of Y-27632 for the culture of CECs, the optimal Y-27632 concentration is yet to be determined. With 30 μM Y-27632, we observed a slight decrease in the cell survival and wound healing of HCECs, compared to those of the HCECs treated with 10 μM Y-27632. Peh et al. had shown a dose-dependent decrease in the attachment strength after the CECs were exposed to more than 30 μM of Y-27632. Therefore, we suggested 10 μM as the optimal concentration of Y-27632 for HCECs cultured by isolating HCEPs.

In conclusion, our results showed that the ROCK inhibitor, Y-27632, enabled the isolation and expansion of HCEPs from peripheral corneal tissue. We observed optimal proliferation and survival of differentiated HCEPs (HCECs) with 10 μM Y-27632. The ROCK inhibitor also induced morphological changes and enhanced wound healing in differentiated HCEPs (HCECs). Further studies are required to evaluate the therapeutic effects of injecting transplantable differentiated HCEPs (HCECs) with Y-27632 in vivo.
Acknowledgements: This research was supported by the Bio & Medical Technology Development Program of the NRF & funded by the Korean government (MSIT) (No.2019M3E5D1A02069616) and by INHA UNIVERSITY HOSPITAL Research Grant

Declaration of Interests: The authors have no financial conflicts of interest.
Figure legends

Figure 1. Isolation and expansion of human corneal endothelial progenitor cells (HCEPs) from the corneal tissue. Phase-contrast images of Y-27632-treated HCEPs at days 1, 6, 13, and 15 (A). Phase-contrast image of cells cultured without Y-27632 (B). Scale bars = 300 μm.

Figure 2. Characterization and expansion of human corneal endothelial progenitor cells (HCEPs). Bipolar and spindle-shaped HCEPs from a 48-year-old donor proliferated during five passages (A). Expression of the HCEPs markers, p75NTR (red) and SOX9 (green) in HCEPs (B). Scale bars = 300 μm.

Figure 3. Characterization and expansion of differentiated human corneal endothelial progenitor cells (HCEPs). Polygonal differentiated HCEPs from a 22-year-old donor were proliferated for seven passages (A). Scale bars = 300 μm. Expression of the differentiated HCEPs functional markers ZO-1 and Na+/K+-ATPase (B, C). Scale bars = 100 μm.

Figure 4. Increased proliferation of differentiated human corneal endothelial progenitor cells (HCEPs) in the presence of 10 μM Y-27632. The differentiated HCEPs were immunostained for the proliferative marker, Ki67 (green), in the presence and absence of Y-27632. Nuclei were counterstained with DAPI (blue) (A). Scale bars = 300 μm. The proliferative capacity of the cells was determined by calculating the ratio of Ki67-positive cells to total DAPI-stained cells (n = 5) (B). *P < 0.05 (Student's t-test).

Figure 5. Enhanced survival of differentiated human corneal endothelial progenitor cells (HCEPs) treated with Y-27632 treatment. The viability of differentiated HCEPs was evaluated using the CCK8 assay, in the presence of different concentrations of Y-27632 (n = 8). *P < 0.05 (One-way ANOVA, followed by Tukey’s test for multiple comparisons).

Figure 6. Morphologic changes in differentiated human corneal endothelial progenitor cells (HCEPs) induced by Y-27632. The differentiated HCEPs were stained with phalloidin in the presence of different concentrations of Y-27632. As the concentration of Y-27632 increased, the differentiated HCEPs lost
their polygonal shape, and became more elongated; the actin filament distribution was also altered. Scale bars = 100 μm.

**Figure 7.** Enhanced wound healing ability of differentiated human corneal endothelial progenitor cells (HCEPs) in the presence of Y-27632. Phase-contrast images of differentiated HCEPs in the wound healing assay in the presence of different concentrations of Y-27632 over 48 h (A). Scale bars = 300 μm.

Kinetics of relative wound closure by differentiated HCEPs treated with different concentration of Y-27632. A significant increase in endothelial wound closure rate was noted when 10 and 30 μM of Y-27632 were added, compared to the control (B). *P < 0.05 (One-way ANOVA; followed by Tukey’s test for multiple comparisons).
REFERENCES


33. Peh GS, Adnan K, George BL, Ang HP, Seah XY, Tan DT, Mehta JS. The effects of Rho-associated kinase inhibitor Y-27632 on primary human corneal endothelial cells propagated using a dual media


